Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia.

Autor: Amaador K; Department of Internal Medicine, UMC Utrecht, Utrecht, The Netherlands., Thieblemont C; Université Paris Cité, Assistance Publique & Hôpitaux de Paris, Paris, France., Trotman J; Department of Haematology, Concord Repatriation General Hospital and Faculty of Medicine and Health, University of Sydney, Concord, New South Wales, Australia., Minnema MC; Department of Hematology, UMC Utrecht, University Utrecht, Utrecht, The Netherlands.
Jazyk: angličtina
Zdroj: Hematological oncology [Hematol Oncol] 2024 Nov; Vol. 42 (6), pp. e3210. Date of Electronic Publication: 2023 Jul 17.
DOI: 10.1002/hon.3210
Abstrakt: Marginal Zone Lymphoma (MZL) and Waldenström's Macroglobulinemia (WM) are indolent lymphomas that both arise from post germinal center lymphocytes. Both can secrete a monoclonal protein but high levels are mostly only seen in WM. The MYD88 L256P somatic mutation that is present in an estimated 95% of patients with WM has helped greatly in differentiating the two lymphomas. Several large clinical studies with new drugs have been performed that have provided new treatment options for both MZL and WM patients. In this short review we will discuss the recent literature published and provide some recommendations.
(© 2023 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: